One platform for precision oncology
With Tempus, we are changing the way precision oncology care is delivered. By leveraging clinical and molecular data, Tempus offers comprehensive genomic profiling services, including somatic testing, minimal residual disease and monitoring, and therapy selection, transforming the way cancer is diagnosed and treated.
Main features
- Solid Tumor + Liquid Biopsy: Maximize biomarker detection and identify more clinically actionable variants linked to targeted therapy options.
- DNA Seq + Whole-transcriptome RNA Seq: Enable a more complete understanding of clinically actionable fusions and altered splicing.
- Solid Tumor + Normal Match: Provides accurate insight through true identification of somatic alterations and maximizes targeted therapy opportunities.
- Minimal Residual Disease & Monitoring: Finely tuned tumor-naive assay to help detect residual disease or recurrence in colorectal cancer. Ultra sensitive assay to monitor residual disease and recurrence, as well as IO treatment response monitoring.
Assays
Genomic profiling services that encompass a broad range of sequencing options, allowing for data-driven patient decisions.
- xT: 648 gene DNA sequencing panel for solid tumors only (includes heme malignancies).
- xR: Whole-transcriptome RNA sequencing panel (includes heme malignancies).
- xF/xF+: 105/523 ctDNA sequencing panel.
- xE: Whole exome, 19,000+ gene DNA sequencing panel.
- xM for MRD: Tumor-naive MRD test for recurrence monitoring in colorectal cancer patients.